<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00027898</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02432</org_study_id>
    <secondary_id>COMIRB 01-288</secondary_id>
    <secondary_id>U01CA099176</secondary_id>
    <secondary_id>CDR0000069091</secondary_id>
    <nct_id>NCT00027898</nct_id>
  </id_info>
  <brief_title>Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I Study of PS-341 (NSC 681239), Carboplatin, and Etoposide in Patients With Advanced Solid Tumors Refractory to Standard Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for their&#xD;
      growth. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Phase I trial to study the effectiveness of combining bortezomib&#xD;
      with carboplatin and etoposide in treating patients who have advanced solid tumors that have&#xD;
      not responded to previous treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose (MTD) of bortezomib, carboplatin, and etoposide in&#xD;
      patients with advanced solid tumors refractory to standard therapy.&#xD;
&#xD;
      II. Evaluate biologic effects of bortezomib on relevant targets in the tumor tissues of&#xD;
      patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of bortezomib, etoposide, and carboplatin.&#xD;
&#xD;
      Patients receive bortezomib IV on days 1 and 8, carboplatin IV over 30 minutes on day 1, and&#xD;
      etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for at least 2&#xD;
      courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bortezomib until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of&#xD;
      6 patients experience dose-limiting toxicity. Once the MTD is determined, 6 additional&#xD;
      patients with newly diagnosed, chemotherapy-naive extensive stage small cell lung cancer, and&#xD;
      6 patients with other tumor types, are treated at that dose.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12-27 patients will be accrued for this study within 6-14&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTD defined as the dose level below the dose level that results in DLT in &gt;= 2 of 6 new patients assessed using NCI CTC version 2.0</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Biological data</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>The variation of these samples as a function of dose and time will be analyzed to define the mathematical function (e.g. linear, exponential, logistic) that best fits and models the data.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment (bortezomib, carboplatin, and etoposide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV on days 1 and 8, carboplatin IV over 30 minutes on day 1, and etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for at least 2 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bortezomib, carboplatin, and etoposide)</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bortezomib, carboplatin, and etoposide)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (bortezomib, carboplatin, and etoposide)</arm_group_label>
    <other_name>EPEG</other_name>
    <other_name>VP-16</other_name>
    <other_name>VP-16-213</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (bortezomib, carboplatin, and etoposide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (bortezomib, carboplatin, and etoposide)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed advanced solid tumor cancer for which no curativetherapy&#xD;
             exists&#xD;
&#xD;
          -  Clinically stable CNS disease is allowed provided the following criteria are met:&#xD;
&#xD;
               -  No uncontrolled brain metastases or CNS involvement&#xD;
&#xD;
               -  No active seizures&#xD;
&#xD;
               -  On stable dose of antiseizure or steroid medication for at least 7 days before&#xD;
                  study enrollment&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No other serious concurrent systemic disorders (including other malignancy)&#xD;
&#xD;
          -  No prior bone marrow or peripheral blood stem cell transplantation&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  Prior carboplatin and/or etoposide allowed&#xD;
&#xD;
          -  No more than 2 prior courses of mitomycin&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Palliative radiotherapy involving less than 35% bone marrow reserve allowed if&#xD;
             completed at least 2 weeks before study enrollment&#xD;
&#xD;
          -  No prior wide-field radiotherapy to 35% or more of bone marrow&#xD;
&#xD;
          -  No prior pelvic radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  At least 28 days since prior investigational agents&#xD;
&#xD;
          -  No other concurrent experimental medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lia Gore</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80217-3364</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>December 7, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 6, 2013</last_update_submitted>
  <last_update_submitted_qc>February 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

